Evidence map›Paper›PMID 39876826›Full record

Observational studyVox sanguinis2025

Use of immunoglobulin G homeostatic set point and recovery time in plasmapheresis donor safety monitoring: A retrospective observational cohort study.

Janet V Warner, Michael J Drinkwater, Gerard J Chu, Shane Kelly, Jeremy S McComish

Abstract readObservational Study
In one paragraph

Observational study in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Janet V WarnerPathology and Clinical Governance, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia.ORCID https://orcid.org/0009-0008-5663-8317
Michael J DrinkwaterSchool of Mathematics and Physics, University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0003-4867-0022
Gerard J ChuPathology and Clinical Governance, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Shane KellyPathology and Clinical Governance, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Jeremy S McComishPathology and Clinical Governance, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSerum immunoglobulin G (IgG) and total protein are used to monitor plasmapheresis donor safety. However, there is a lack of information from large donor cohorts to determine the best use of these measurements. MATERIALS AND

methodsWe identified 230,144 plasmapheresis donors making their first donation between 1 July 2020 and 31 March 2024. IgG and total protein were measured prior to the first donation and then annually, following our donor safety monitoring protocol. We considered individuals who had not donated for 12 months to estimate intra-individual biological variability of IgG. We compared four models to predict which donors would develop IgG < 6 g/L.

resultsThe IgG reference interval for the cohort was 7.67-15.6 g/L. IgG declines 5%-11% after the age of 45 years. The intra-individual biological variability of IgG (5.2%) is small, indicating that there is homeostatic set point for individual IgG. IgG is reduced by plasmapheresis but recovers to recruitment level after 12 weeks. When plasma is donated every 2-3 weeks, mean IgG plateaus 1 g/L below recruitment concentration. IgG at recruitment is the best predictor of which donors will have IgG < 6 g/L after a year of donations. Total protein is a low-value test in this context.

conclusionPlasmapheresis is safe and sustainable for almost every donor, at the 2-weekly frequency allowed in Australia. The donors most likely to experience unacceptably low IgG are those with very low recruitment IgG levels. These donors could be recommended 12-week intervals between donations or other donation types.

Indexed as

Blood DonorsImmunoglobulin GPlasmapheresisAdultFemaleHomeostasisHumansMaleMiddle AgedRetrospective StudiesImmunoglobulin Ghomeostatic set pointimmunoglobulin Gindividual biological variabilityplasma donationplasmapheresis donor

Identifiers

PMID39876826
PMCPMC12017950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.